Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
82 results about "Ocular neovascularization" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
InactiveUS20060189608A1Highly potent and efficacious inhibitionBiocideSenses disorderDiseaseReceptor tyrosine kinase inhibitor
The present invention provides compositions and methods for treating ocular neovascularization, angiogenesis, retinal edema, diabetic retinopathy, and / or retinal ischemia in order to prevent the loss of visual acuity associated with such conditions. More specifically, the present invention provides compositions containing receptor tyrosine kinase (RTK) inhibitors having unique binding profiles and their use in treating ocular disorders.
Owner:NOVARTIS AG
Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
InactiveUS7517870B2High unmet needControl rateBiocideOrganic active ingredientsDiabetic retinopathyHedgehog signaling pathway
The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and / or reversing ocular diseases related with ocular neovascularization. Particularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity (ROP).
Owner:FOND AZIONE TELETHON
Use of angiostatic steroids in photodynamic therapy
Methods for treating ocular neovascularization using photodynamic therapy in combination with an angiostatic steriod are disclosed.
Owner:ALCON RES LTD
Treatment of AMD using aav sflt-1
InactiveUS20130323302A1Compounds screening/testingOrganic active ingredientsOcular neovascularizationMedicine
The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
Owner:AVALANCHE AUSTRALIA
PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
InactiveUS20070149593A1Increase vascular permeabilityOvercomes drawbackBiocideSenses disorderDiseaseOcular neovascularization
The present invention relates to development of efficacious intravitreal pharmaceutical compositions comprising a poorly water soluble agent with anti-angiogenic and / or anti vascular leakage properties in a therapeutically effective amount and a co-solvent in a suitable amount to treat or prevent diseases due to ocular neovascularization and enhanced vascular permeability. Other aspects of the invention details the development of efficacious compositions for the treatment of the said diseases via periocular, topical and oral administration.
Owner:ALCON INC
Therapeutic dll4 binding proteins
ActiveUS20110117079A1High affinityEliminate needAntibacterial agentsSenses disorderDiseaseTumor angiogenesis
Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and / or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Owner:ABBVIE INC
PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
InactiveUS20070173538A1Less invasive procedureDesirable bioavailabilityBiocideSenses disorderOcular neovascularizationPharmaceutical formulation
The present invention relates to development of efficacious pharmaceutical compositions comprising a poorly water soluble active compound in a therapeutically effective amount and a co-solvent in a suitable amount to treat or prevent diseases due to ocular neovascularization and enhanced vascular permeability. In preferred aspects the composition is in the form of a gel.
Owner:ALCON INC
1,2,4-triazole derivatives, compositions, process of making and methods of use
Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.
Owner:GLAXO SMITHKLINE LLC
Tek antagonists
InactiveUS7067475B2Inhibit angiogenesisHigh binding affinityBiocidePeptide/protein ingredientsOcular neovascularizationMammal
The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.
Owner:IMMUNEX CORP
Nitric acid ester medicament for inhibiting angiogenesis
ActiveCN101412742AOrganic active ingredientsPharmaceutical non-active ingredientsDiseaseAbnormal tissue growth
The invention relates to a nitric acid ester drug for inhibiting the regeneration of blood vessels. The drug is the compound 1, ester or salt of the compound with the following general formula: T-(B-O-NO2)t1, wherein t1 is 1 or 2; T-H is a steroids compound; T is a residual steroids radial of the compound 1 after removing H, and T and H are connected in the form of O-H, namely connecting an oxygen atom on T and H, to form a hydroxide radical The compound is used for preparing the drug for treating tumor and ocular neovascularization disease.
Owner:TIANJIN JINYAO GRP
Use of compounds that interfere with the Hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
InactiveUS20060276391A1High unmet needControl rateBiocideOrganic active ingredientsDiabetic retinopathyHedgehog signaling pathway
The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and / or reversing ocular diseases related with ocular neovascularization. Partcularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity (ROP).
Owner:FOND AZIONE TELETHON
Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
InactiveUS6846839B1Relieve symptomsMinimize angiogenesisBiocideOrganic chemistryWound healingLymphatic Spread
The present invention relates to methods for treating diseases and disorders related to unregulated angiogenesis and / or vasculogenesis. More specifically, this invention relates to methods for treating diseases and disorders, such as rheumatoid arthritis, endometriosis, ocular neovascularization, solid tumor growth and metastases, and excessive scarring during wound healing, with indolinone compounds.
Owner:SUGEN INC
Method to prevent vision loss
InactiveUS7060695B2Loss in acuityReduced acuityBiocideElectrotherapyPhotodynamic therapyOcular neovascularization
An improved method to treat conditions of the eye characterized by ocular neovascularization is provided in which patients are given and initial photodynamic therapy (PDT) treatment to destroy the neovasculature, and then are re-evaluated at least twice during the following 6 months, and retreated as necessary. Preferably, three retreatments are provided.
Owner:AZAB MOHAMMAD +2
Tetracycline derivatives for the treatment of ocular pathologies
InactiveUS20050256081A1Reduce ocular neovascularizationReduce neovascularizationBiocideSenses disorderConjunctivaOcular neovascularization
Formulations and methods useful to reduce ocular neovascularization (new blood vessels in the cornea, retina, conjunctiva, and / or choroid) are disclosed. According to the invention the formulation will include tetracycline or a derivative thereof including chemically modified tetracyclines (CMT) which inhibit matrix metalloproteinase (MMP) activity at a substantially neutral pH in a pharmaceutically acceptable form suitable for delivery to the eye in an amount and for a duration sufficient to reduce ocular neovascularization. According to the invention the formulations are preferably in pharmaceutically acceptable formulations for topical ocular application, ocular injection, or ocular implantation, and may be contained in liposomes or slow release capsules.
Owner:MINU
Dual Targeted siRNA Therapeutics for Treatment of Diabetic Retinopathy and Other Ocular Neovascularization Diseases
InactiveUS20130123330A1Organic active ingredientsFermentationDiabetes retinopathyOcular neovascularization
The present invention relates to compositions and methods for treating diabetic retinopathy and other ocular neovascularization diseases. In one embodiment, the composition comprises at least two different siRNA duplexes and a pharmaceutically acceptable carrier. One of the duplexes binds to an mRNA molecule that encodes VEGF, and the other binds to an mRNA molecule that encodes VEGFR2. In another embodiment, the composition further comprises an siRNA duplex that binds to an mRNA molecule that encodes TGFβ1.
Owner:LU PATRICK Y +2
Photodynamic therapy for ocular neovascularization
InactiveUS20060258629A1Facilitate photodynamic therapyEnhancing photodynamic therapyBiocideElectrotherapyPhotodynamic therapyMedicine
Owner:RGT UNIV OF CALIFORNIA
Triazole inhibitors of type 2 methionine aminopeptidase
Disclosed are compounds which are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.
Owner:SMITHKLINE BECKMAN CORP
Compositions and methods for treatment of macular degeneration and related conditions
InactiveUS20090117171A1BiocideOrganic active ingredientsOcular neovascularizationOcular inflammation
The present invention provides methods and compositions for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. The methods comprise administering a composition comprising a compound that is an antagonist of a G protein coupled receptor, e.g., the C5a receptor, to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization. The invention provides compositions comprising a compound that is an antagonist of a G protein coupled receptor linked either directly or indirectly to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization.
Owner:POTENTIA PHARMA INC
Methods for treating ocular neovascular diseases
InactiveUS20070027101A1Treatment safetyStable and improved visionSenses disorderElectrotherapyPhotodynamic therapyOcular neovascularization
Disclosed herein are methods for treating ocular neovascular disease using anti-VEGF therapy in combination with a second therapy that inhibits the development of ocular neovascularization or destroys abnormal blood vessels in the eye, such as photodynamic therapy.
Owner:EYETECH
Heparin for the treatment of ocular pathologies
InactiveUS20060122152A1Reducing ocular neovascularizationReduce neovascularizationBiocideTetracycline active ingredientsConjunctivaIntraocular pressure
Formulations and methods useful to treat ocular neovascularization (new blood vessel growth in the cornea, retina, conjunctiva, and / or choroid) are illustrated. According to the invention there is provided a formulation suitable for the treatment of ocular neovascularization that may comprise heparin in a concentration and dose suitable for treating ocular neovascularization, characterized in that said compound is at a substantially neutral pH in a pharmaceutically acceptable form suitable for delivery to the eye. Use of drugs like steroids in the treatment of such ocular neovascularization ailments can increase intraocular pressure (glaucoma).
Owner:MINU
Tek antagonists
InactiveUS20070025993A1Organic active ingredientsSenses disorderOcular neovascularizationAngiogenesis growth factor
The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.
Owner:IMMUNEX CORP
Delivery of nrf2 as therapy for protection against reactive oxygen species
ActiveUS20170088593A1Polypeptide with localisation/targeting motifPeptide/protein ingredientsOcular neovascularizationOcular inflammation
The present invention provides methods and compositions for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or inflammation, including ocular inflammation. In some embodiments, the methods comprise administering an expression vector that delivers a secretable and cell penetrating Nrf2 to a subject in need thereof.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Materials and methods for treating ocular-related disorders
The present invention is directed to a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder, e.g., ocular neovascularization or age-related macular degeneration. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and the same or different nucleic acid sequence encoding a neurotrophic agent. The method also can comprise contacting an ocular cell with different expression vectors, each comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and / or a nucleic acid sequence encoding a neurotrophic agent. In addition, the present invention provides a viral vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) or a therapeutic fragment thereof.
Owner:GEN VEC INC
Compounds and methods
InactiveUS20050143578A1Useful in preparationOrganic active ingredientsSenses disorderOcular neovascularizationMethionine aminopeptidase
Disclosed are compounds of the formula: wherein the formula variables are as defined herein. The compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase. Also disclosed is the use of such compounds in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.
Owner:SMITHKLINE BECKMAN CORP
Treatment of AMD using aav sflt-1
InactiveUS20140341977A1Compounds screening/testingOrganic active ingredientsOcular neovascularizationMedicine
The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
Owner:AVALANCHE AUSTRALIA PTY LTD
Ocular Formulations for Drug-Delivery to the Posterior Segment of the Eye
ActiveUS20140303219A1Reduce exposureImprove bioavailabilityOrganic active ingredientsBiocideOcular neovascularizationOphthalmology
The present invention relates to topical formulations comprising a compound of the following formula:for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w / v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and / or the choroid.
Owner:PANOPTICA
1,2,4-triazole derivatives, compositions, process of making and methods of use
Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.
Owner:GLAXO SMITHKLINE LLC
Medicament for slowing down angiogenesis of eye section
The invention relates to an application of a steroid compound to a medicine for inhibiting the generation of ocular neovascularization. The preparation of preparations related to the medicine is also related.
Owner:TIANJIN PHARMA GROUP CORP
Antiprostaglandins for the treatment of ocular pathologies
Formulations and methods useful to treat ocular neovascularization (new blood vessel growth in the cornea, retina, conjunctiva, and / or choroid) are disclosed. According to the invention there is provided a formulation suitable for the treatment of ocular neovascularization that may comprise flurbiprofen in a concentration and dose suitable for treating ocular neovascularization, characterized in that said flurbiprofen may be at a substantially neutral pH in a pharmaceutically acceptable form suitable for delivery to the eye.
Owner:MINU
Virus-mediated delivery of bevacizumab for therapeutic applications
InactiveUS20130090375A1Reduction in total area of neovascularizationReduce neovascularizationOrganic active ingredientsSenses disorderBevacizumab InjectionOphthalmology
The invention provides a method of inhibiting ocular neovascularization in a mammal by administering a composition comprising a bevacizumab-encoding adeno-associated virus (AAV) vector directly to the eye of the mammal.
Owner:CORNELL UNIVERSITY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com